CRISPR Therapeutics Q2 Earnings Miss: Casgevy Gene Therapy Sales in Focus

CRISPR Therapeutics shares fell in the premarket after Q2 2025 financials missed expectations, with investors focusing on sales from its Casgevy gene editing therapy developed with Vertex Pharma. The company reported lower-than-expected revenue, with a focus on the gene therapy's performance.

Shares of CRISPR Therapeutics (NASDAQ:CRSP) continued to drop in the premarket on Tuesday following the Swiss biotech's release of lower-than-expected Q2 2025 financial results. The company's stock faced significant selling pressure as investors focused on the performance of its Casgevy gene editing therapy, developed in collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX).

In the aftermarket hours on Monday, CRISPR (NASDAQ:CRSP) reported $0.9M in revenue for the quarter, representing a 71% year-over-year (YoY) growth, but this figure fell short of the consensus estimate by $5.6M. Vertex (NASDAQ:VRTX) reported $30.4M in revenue from Casgevy, indicating worldwide sales including the U.S., for sickle cell disease or transfusion-dependent beta thalassemia. Casgevy's revenue for the quarter marked a significant milestone, with 16 patients receiving infusions in the second quarter alone, contributing to a global rollout of 75 authorized treatment centers.

Despite the revenue shortfall, CRISPR's bottom line also faced challenges. The company's GAAP net loss per share surged by 61% YoY to $2.40, exceeding the consensus estimate by $1.01. This increase was primarily attributed to $96.3M of acquired in-process R&D expenses resulting from its recent collaboration with Sirius Therapeutics, an RNA-based drug developer.

The collaboration with Sirius Therapeutics is part of CRISPR's broader strategy to expand its gene-editing portfolio and explore new therapeutic areas. However, the financial results suggest that the company may need to address the costs associated with these collaborations and ensure that they align with revenue expectations.

The market reaction to CRISPR's Q2 2025 financials underscores the importance of meeting revenue and profitability targets, particularly in the biotechnology sector where investor expectations are often high. CRISPR will need to provide clear guidance on its future financial performance and the expected impact of its collaborations to reassure investors.

[1] https://seekingalpha.com/news/4478289-crispr-stock-falls-q2-miss